ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.
Female patients aged ≥18 years
ECOG performance status 0-2
Histologically proven diagnosis of high grade serous or high grade endometrioid carcinoma of the ovary, fallopian tube or peritoneum
Most recent regimen must have included platinum (cisplatin or carboplatin)
Non-epithelial ovarian cancer, carcinosarcoma, low-grade serous and endometrioid carcinomas, mucinous & clear-cell carcinomas
Patients requiring treatment with combination chemotherapy regimens
Patients with a known hypersensitivity to carboplatin
Persisting ≥ grade 2 CTCAE v5 adverse events/ toxicity (except alopecia and neuropathy) from previous anti-cancer treatment.
University College, London
Lead sponsor
Anticancer Fund, Belgium
Collaborator
JP Moulton Charitable Foundation
Collaborator
Barts & The London NHS Trust
Collaborator